Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.

Radhakrishnan, Suresh

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. [electronic resource] - Human gene therapy Oct 2010 - 1311-25 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1557-7422

10.1089/hum.2010.019 doi


Adenovirus E1A Proteins--genetics
Adenovirus E1B Proteins--genetics
Adenoviruses, Human--drug effects
Animals
Antineoplastic Agents--pharmacology
Cell Cycle--drug effects
Cell Death--drug effects
Cell Line, Tumor
Combined Modality Therapy
Docetaxel
Flow Cytometry
Gene Expression
Genes, p53
Humans
Immunoblotting
Male
Mice
Mice, Nude
Mitoxantrone--pharmacology
Neoplasm Transplantation
Oncolytic Virotherapy--methods
Oncolytic Viruses--drug effects
Polymerase Chain Reaction
Prostatic Neoplasms--drug therapy
Retinoblastoma Protein--metabolism
Taxoids--pharmacology
Transplantation, Heterologous
Tumor Suppressor Protein p53--metabolism
Virus Replication--drug effects